Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an ...

Emergent BioSolutions (EBS) announced that it is raising awareness of the Ready to Rescue initiative in New Orleans with pro football legend ...

Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, then turning it around and ultimately transforming the company,” Papa told the ...

In the assessment of 12-month price targets, analysts unveil insights for Emergent BioSolutions, presenting an average target of $14.25, a high estimate of $15.00, and a low estimate of $12.00.

Emergent BioSolutions is committed to increasing access to naloxone products and continuing to fight the opioid epidemic by ensuring that both NARCAN and KLOXXADO are readily available.

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE ... the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is ...

raising awareness and ensuring strong supply to meet the ongoing demand of naloxone nasal spray GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...